⏳ Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Mother fights brain cancer with electric fields

Published 06/02/2015, 04:07 PM
Mother fights brain cancer with electric fields

By Ben Gruber

ST. LOUIS MISSOURI - Against all odds, Elizabeth Marek is alive thanks to a tumor-killing device that attacks brain cancer cells with electric fields. Marek has glioblastoma, a deadly and aggressive form of brain cancer with no cure and a life expectancy of just over two years.

Twenty-six weeks pregnant with her second child, 3 years after a small tumor was found in her brain, Marek began suffering from extreme headaches. She thought it was migraines due to pregnancy.    

"It ended up being a tumor that was the size of my fist on the left side of my brain and it was pushing the left brain into the right brain area," she said. 

A team of oncologists and surgeons at Washington University in St. Louis, Missouri successfully removed the tumor during an emergency surgery and then waited 8 weeks to allow Marek's daughter more time in the womb before starting radiation and chemotherapy treatments. 

After the second round of chemotherapy, a new tumor started forming in Marek's brain. That is when Dr. George Ansstas offered her a chance to be a science experiment.

"I have always wanted to be in science. I didn't know I was going to be an experiment," Marek joked. 

Ansstas fitted Marek with a device called Optune, developed by U.S.-based oncology firm Novocure. A backpack feeds to an array of electrodes attached to Marek's head. Those electrodes create an electric field inside her brain which stops cell division in cancer cells. 

"There are highly charged particles in the cells that play a role in division and if you expose those cells to this electromagnetic field you might disrupt that process and lead cells to death," Ansstas explained.

In clinical trials the device, used in combination with conventional treatments, extended patients lives by an average of three months. 

"Also when we look at those patients at two years about 43 percent of those patients survive, that is something that has not been seen before," Ansstas added. 

43 percent compared to 29 percent with patients that didn't use the device during the trial period. The results of the trial are being presented this week at the American Society of Clinical Oncology annual meeting in Chicago. The device has been approved by the U.S. Food and Drug Administration (FDA) to treat adult patients with recurrent glioblastoma. More than 2000 patients are currently using the device, according to Novocure.  

For Marek the results have been dramatic.

"The first time I got results back after using it for two weeks, I had a 30 percent reduction in my tumor size," she said. 

According to her doctors, Marek currently has no measurable signs of cancer in her brain. She has been wearing the device for a year and says apart from the odd looks, her life is back to normal.

"The only thing that is different about me is that I carry around a backpack that is putting electrodes into my brain. That way if little kids say 'oh what is that for, what is that for'  I say that's my battery for my brain," she said. 

There are no studies about the long term efficacy of her electric cancer fighter and in that sense Elizabeth is a pioneer, counting her blessings and enjoying her family one day at a time. In an effort to continue funding Elizabeth's treatment, the Marek family is collecting donations at www.gofundme.com/goelizabeth. OLUSSCIENCE Reuters US Online Report Science News 20150602T200704+0000

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.